
Opinion|Videos|December 23, 2024
Final Thoughts: The Spesolimab and GPP Flare Reduction
Key Takeaways
Panelists discuss how the Effisayil 2 trial's results suggest that spesolimab offers a promising strategy for reducing the frequency and severity of GPP flares, potentially revolutionizing the management of this severe and life-threatening condition.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
New Consensus Defines Remission, Disease Activity in Atopic Dermatitis
2
Real-World Study Finds Experienced Dermatologists Outperform AI in Skin Cancer Diagnosis
3
Zasocitinib Shows High Skin Clearance at Hard-to-Treat Psoriasis Sites
4
Beyond Retinol: Evaluating the Stability, Safety, and Gene-Expression Profile of Bakuchiol Ferulate
5












